Navigation Links
Met-Pro Corporation Declares Quarterly Dividend

HARLEYSVILLE, Pa., Dec. 4 /PRNewswire-FirstCall/ -- Raymond J. De Hont, Chairman and Chief Executive Officer of Met-Pro Corporation (NYSE: MPR), announced today that the Company's Board of Directors, at their meeting on December 3, 2008, declared a quarterly dividend of $0.06 per share payable on March 12, 2009 to shareholders of record at the close of business on February 26, 2009. This dividend represents a 9.1% increase over the same period last year.

This is the thirty-fourth consecutive year that Met-Pro Corporation has paid either a cash or stock dividend.

About Met-Pro

Met-Pro Corporation, with headquarters at 160 Cassell Road, Harleysville, Pennsylvania, was recently recognized, for the third consecutive year, as one of America's "200 Best Small Companies" by Forbes magazine. The Company was also named earlier this year as one of the world's "Top Small to Midsize Manufacturers" by Start-It magazine for the second year in a row. Through its business units, in the United States, Canada, Europe and The People's Republic of China, a wide range of products and services are offered for industrial, commercial, municipal and residential markets worldwide. These include product recovery and pollution control technologies for purification of air and liquids; fluid handling technologies for corrosive, abrasive and high temperature liquids; Mefiag filtration technologies for harsh, corrosive liquid filtration applications; and filtration and purification technologies which include proprietary water treatment chemicals and filter products for air and liquid filtration. For more information, please visit

The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Certain information included in this news release, and other materials filed or to be filed with the Securities and Exchange Commission (as well as information included in oral or other written statements made or to be made by the Company), contain statements that are forward-looking. Such statements may relate to plans for future expansion, business development activities, capital spending, financing, the effects of regulation and competition, or anticipated sales or earnings results. Such information involves risks and uncertainties that could significantly affect results in the future and, accordingly, such results may differ from those expressed in any forward-looking statements made by or on behalf of the Company. These risks and uncertainties include, but are not limited to, those relating to, the cancellation or delay of purchase orders and shipments, product development activities, computer systems implementation, dependence on existing management, the continuation of effective cost and quality control measures, retention of customers, global economic and market conditions, and changes in federal or state laws.

Met-Pro common shares are traded on the New York Stock Exchange, symbol MPR.

To obtain an Annual Report or additional information on the Company, please call 215-723-6751 and ask for the Investor Relations Department, or visit the Company's website at

    Contact:  Investor Contact:
              Gary J. Morgan,
              Senior Vice President of Finance, CFO

              Joseph Hassett, VP
              Gregory FCA Communications

SOURCE Met-Pro Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Met-Pro Corporations Fybroc Business Unit Receives Equipment Order Totaling Approximately $500,000
2. Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
5. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
6. BioElectronics Corporation Announces Singapore and Malaysia Sales
7. Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds
8. DURECT Corporation to Present at the NewsMakers in the Biotech Industry Investment Conference
9. Insulet Corporation to Present at the Thomas Weisel Partners Healthcare Conference on September 6, 2007
10. Luminex Corporation to Present at Thomas Weisel Partners Healthcare Conference
11. Verenium Corporation to Present at the Upcoming Cowen and Company Clean Energy Conference
Post Your Comments:
(Date:10/9/2017)... ... 09, 2017 , ... The award-winning American Farmer television series will feature 3 ... airs Tuesdays at 8:30aET on RFD-TV. , With global population estimates nearing ten ... to continue to feed a growing nation. At the same time, many of our ...
(Date:10/9/2017)... ... October 09, 2017 , ... ... 2017, in the medical journal, Epilepsia, Brain Sentinel’s SPEAC® System which uses ... EEG, in detecting generalized tonic-clonic seizures (GTCS) using surface electromyography (sEMG). The ...
(Date:10/7/2017)... 2017  The 2017 Nobel Prize in Chemistry ... Dubochet, Joachim Frank and Richard ... microscopy (cryo-EM) have helped to broaden the ... community. The winners worked with systems manufactured by ... highly resolved, three-dimensional images of protein structures that ...
(Date:10/5/2017)... ... , ... LabRoots , the leading provider of educational and interactive virtual ... to cancer research with a month-long promotion supporting the advancement of breast cancer research ... use promo code PinkRibbon to get 10 percent off their purchase of every the ...
Breaking Biology Technology:
(Date:4/13/2017)... According to a new market research report "Consumer IAM Market by Solution ... Authentication Type, Deployment Mode, Vertical, and Region - Global Forecast to 2022", ... 14.30 Billion in 2017 to USD 31.75 Billion by 2022, at a ... ... MarketsandMarkets Logo ...
(Date:4/6/2017)... Forecasts by Product Type (EAC), Biometrics, Card-Based ... & Logistics, Government & Public Sector, Utilities / Energy ... Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality & ... for a definitive report on the $27.9bn Access Control ... ...
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
Breaking Biology News(10 mins):